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Thymus-derived lymphocytes (T cells)  have been shown  to perform a  variety of 
immunological functions  in an antigen-specific manner (1).  To explain such immu- 
nological specificity on a chemical basis, it is necessary to postulate the existence of a 
class of molecules on the T-cell surface which have specific affinity to relevant antigens 
by virtue of their structural diversity, i.e., T-cell receptors. Available information on 
the nature of T-cell receptors has been sparse and controversial. Nevertheless, accu- 
mulating evidence, mainly obtained by idiotypic analyses, suggests a role of Ig heavy 
chain-linked Igh-V 2 gene products in the antigen-combining sites of T-cell receptors, 
although  conventional  immunoglobulin  determinants  have not  been  demonstrated 
(2 -4). 
Antibodies to constant region determinants of immunoglobulins are known to block 
binding of antigen by B cells (5).  Thus, if T-cell receptors also have constant regions, 
antibodies  to such determinants  might interfere with achievement of T-cell effector 
functions by blocking receptor-antigen interactions. Of course, antibodies to other cell 
surface molecules might also exert similar inhibitory effects on effector cell functions. 
The effector function of cytotoxic T  cells in allogeneic cell-mediated lymphocyto- 
toxicity (CML) a reactions have previously been shown to be insensitive to treatment 
with  a  variety of antibodies  in  the  absence of complement  (6).  Attempts  to  block 
allogeneic  CML  by  alloantibodies  reactive  with  killer  cells  have  been  uniformly 
unsuccessful, indicating that coating killer cells with antibodies is generally insufficient 
to  affect  the  effector  function.  There  have  been  two  positive  reports  indicating 
inhibition  of CML by xenogeneic antisera at  the  killer cell  level  in  the absence of 
complement  (7,  8), although  the target molecules responsible for such  inhibition  or 
gene(s) encoding such molecules were not characterized. 
If alloantibodies with such inhibitory activity could be raised, they would undoubt- 
edly provide a  more useful  tool than xenoantibodies  for analysis of the nature  and 
genetics of molecules involved in cytotoxic T-cell effector function. Therefore, attempts 
were made to raise mouse alloantisera capable of inhibiting allogeneic CML in  the 
* The nomenclatures of immunoglobulin genes used in this paper conform to those proposed by Green 
et al. Green, M. G. et al., Immunogenetics. In press. 
Abbreviations used m this paper: CML, cell-mediated lymphocytotoxicity;  B6, C57BL/6; B 10, C57BL/10; 
CWB, C3H.SW/Hz[GIB; MLR, mixed leukocyte reaction. 
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absence of complement. Hyperimmune anti-lymphocyte sera raised in various strain 
combinations of mice were tested  for their ability to inhibit allogeneic CML  using 
killer-target combinations chosen to assess the effect on killer cells. Although most of 
our attempts were  unsuccessful, we succeeded in raising mouse alloantisera in one 
strain combination which had the requisite properties. In this paper we describe the 
properties of these sera and an analysis of the linkage relationships of genes coding for 
the antigens on the cytotoxic T  cells responsible for the observed inhibitory effect. 
Materials and Methods 
Mice.  Adult mice, 8-10 wk old, of both sexes were used. Mice of strains AKR/N, BALB/ 
cN, C57BL/6N (B6), C3H/HeN, and DBA/2N were obtained through the National Institutes 
of Health Small Animal Section. Strains A/J, C57BL/10 (B10), B10.BR, B10.D2,  C3H/HeJ, 
C3H.SW, and CBA/J were produced in our animal colony. BALB.B mice were kindly provided 
by Dr. M. Potter, National Cancer Institute, and C3H.SW/HzlGIB (CWB)  mice were kindly 
supplied by Doctors L. Herzenberg, Stanford University, and M. Bosma, Fox Chase Institute. 
B6.Ly2.1  mice were produced in our colony from stock kindly supplied by Dr.  E. A. Boyse, 
Sloan-Kettering Institute. 
Immunization.  Recipient mice were immunized with a mixture of thymus, spleen, and lymph 
node cells of normal donor mice, or with cells sensitized repeatedly with allogeneic cells in vitro. 
Immunizations consisted of 2-5  X  107 cells in 0.1  ml injected i.p. at  I- to 2-wk intervals. For 
the first  immunization, the cell suspension was emulsified in an equal volume of complete 
Freund's adjuvant, and subsequent immunizations  were administered without adjuvant. 7-8 d 
after each immunization,  mice were bled from the tails. Sera from individual mice were pooled, 
unless otherwise mentioned, decomplemented (56°C for 30 min), and were screened for CML- 
inhibiting activity. 
Target Cells.  Normal spleen cells and tumor cells were used as target cells for CML assays. 
K46 BALB/c tumor cell line (9) was kindly provided by Dr. J. Kim and maintained in culture. 
100/~Ci of SXCr in 0.1  ml was added to  1 ml of cell suspension containing 2  ×  107 cells. The 
mixture was incubated at 37°C for 1 h and washed three times with 15 ml of medium. 
CML Assay.  4 million splenic responder cells were cultured with 2 X  106 irradiated splenic 
stimulator cells in 2 ml of Eagle's minimal essential medium supplemented with glutamine, 
nonessential amino acids, sodium pyruvate, 0.05 mM 2-mercaptoethanol, antibiotics, 10 mM 
Hepes, and 10% heat-inactivated fetal calf serum in humidified 1% CO2 in air at 37°C for 5 d. 
When a large number of cells was required, 1.4  X  l0  s responders and 7 X  107 stimulator cells 
were cultured in 70 ml of medium in a  250-ml plastic tissue culture flask. Cytotoxic activity 
was assessed  in microtiter plates containing 2  ×  104 5~Cr-labeled  target cells  in 0.1  ml and 
graded numbers of attacker cells in 0.1  ml per well  in triplicates. Cytotoxie activity of each 
killer population was titrated in every experiment. The plates were centrifuged at 20 g for 2 
rain  at  room  temperature  and  incubated for  4  h  at  37°C.  Cultures were  terminated by 
centrifugation at  800 g  for  10  min at  4°C.  Supernates were  collected  using the  Titertek 
Supernatant Collection System (Flow Laboratories, Inc., Rockville, Md.), and were counted in 
a  Searle gamma counter (Searle  Diagnostics Inc., subsid, of G. D.  Searle & Co., Des Plaines, 
Ill.). Maximum releasable SlCr was measured by incubating  targets in 2.5% Triton X-100 (New 
England Nuclear, Boston, Mass.).  Specific percent lysis was calculated as: 
experimental release  -  spontaneous release 
X  100. 
maximum release 
Blocking of CML by Antisera.  20/tl of decomplemented serum was placed in microtiter wells 
in triplicate and  100/tl of cell suspension containing 1.6  X  105 attackers were added.  After 
shaking the  plate, 5~Cr-labeled  target  cells  in  100 ttl  were  added  and the CML assay was 
performed as described above. Fetal calf serum used in all experiments was decomplemented 
(56°C for 30 min). 
Complement-mediated Cytotoxicity Assay.  Trypan  blue cytotoxicity tests  were  performed  as 
previously described (10). Briefly,  25 #1 of serially diluted serum and 25/zl of cell suspensions 434  BLOCKING  CYTOTOXIC  T-CELL  FUNCTION 
TABL~  I 
Summary of Attempts to Raise CML-blocking Mouse Alloantibodies* 
Strain combination  GeneticS: difference  Maximal§ cytotox-  Inhibition 
icity  of CML 
BALB/c a-B6  H-2  +  non-H-2  >90% 1:2,042  -,  +]] 
A/J a-BI0.D2  "  >90% 1:256  -,  __. 
CBA/J a-B 10  "  >90% 1:8,000  - 
B10.D2 a-BI0.BR  H-2  >90% 1:128  -- 
C3H/HeJ a-C3H.SW  "  >90% 1:5,120  -,  -+ 
BALB/c a-BI0.D2  Non-H-2  >90% 1:128  - 
DBA/2 a-BALB/c  "  50% 1:512  - 
DBA/2 a-B 10.D2  "  40%1:256  - 
A/J a-BI0.A  "  >90% 1:64  - 
C3H/HeJ a-CBA/J  "  60% l : 128  - 
CBA/J a-C3H/HeJ  "  70%1:64  - 
CBA/J a-B10.BR  "  >90% 1:512  -,  + 
C3H/HeJ a-B10.BR  "  >90% 1:1,024  -,  +  +¶ 
C3H/HeN a-BI0.BR  "  >90% 1:512  -,  +  + 
CB-20 a-BALB/c  Igh-C  <10%  - 
BALB/c a-CB-20  "  < 10%  - 
(PL/J  x  B6.PL-Thyla)F1 a-B6  Thy-I  >90% 1:256"*  - 
BALB/c a-(B6 a-BALB/c) cells~:  H-2  +  non-H-2  >90% 1:512  - 
B6 a-(BALB/e a-B6) cells~:  "  >90% 1:256  - 
(DBA/2  ×  B6)FI ~-(B6 ~-DBA/2) cells:]:~  None 
* Animals of each group received 8-18 immunizations. Decomplemented pooled sera collected after each 
immunization were tested for their ability to inhibit CML in the absence of complement. Killer-target 
combinations were chosen so that the antisera should react only with the killer population. For details, 
see Materials and Methods. 
Genetic differences between the donors and the recipients. 
§ Complement-dependent  cytotoxicity  of the  serum  on  donor  spleen  cells  which  showed  the  highest 
cytotoxic activity among the sera obtained within the immunization group. The left column shows the 
maximum percent  of spleen cells killed  by the serum. The right  column  indicates  reciprocal  of the 
maximal dilution of the serum required to kill more than one-half of the maximum killing. 
[] Inhibition with marginal significance or with poor reproducibility. 
¶ Some sera showed significant and reproducible inhibition. 
** Cytotoxicity on thymocytes. 
:~:~ Immunized with in vitro sensitized cells. 
were mixed and incubated for  15 min at 37°C. Wells were washed and rabbit complement  was 
added,  followed by another 30-min incubation at 37°C. Cell death was determined microscop- 
ically by trypan blue uptake. 
Results 
Hyperimmune  mouse  alloantisera  were  raised  in  various  strain  combinations 
including  H-2  and  non-H-2  incompatible  pairs.  Some  animals  were  immunized  with 
cells which  had  been  sensitized  to allogeneic  cells three  times  in vitro.  These  sera were 
tested  for their  ability  to inhibit  allogeneic  CML  when  added  to CML  cultures  in the 
absence  of complement,  using strain  combinations  chosen  to assess effects on the killer 
cells. Over  150 sera  raised  in  20  different  combinations  were  screened  and  results  are 
summarized  in Table  I.  Most  of these sera failed  to show  any  significant  or reproduc- 
ible  inhibitory  effect,  although  many  of  them  proved  to  have  fairly  high-titered 
antibodies  reactive  with  100%  of donor  spleen  cells  in  complement-dependent  cyto- NOBUKATA SHINOHARA  AND  DAVID H.  SACHS 
TABLE II 
Inhibition of CML by a C3H Anti-B I O.BR Serum* 
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Killer-target combination 
B6 
Inhibitor  a-BALB  B l0 a-C3H on C3H  B 10 a-BALB on K46 
on BALB 
Exp. I  Exp. 2  Exp. 3  Exp. 4  Exp. 5 
None  20.8 +  2.4:[:  11.9 ±  0.6  17.3 ±  1.1  33.9 ±  3.8  46.5 ±  0.7 
NMS§  21.3 ±  1.7  11.4 ±  1.9  19.1  ±  5.0  27.2 ±  0.7  45.1  ±  3.3 
NI8-1 (C3H a-B10.BR)  8.2 ±  2.0  0.2 ±  0.4  8.9 ±  1.0  14.5 ±  0.7  21.4 ±  1.5 
* For details see Materials and Methods. 
:]: Percent specific release ±  SD, in the presence of the indicated serum. 
§ Normal mouse serum. 
toxicity assays. These results suggested that coating of killer cells with antibodies was 
not sufficient to interfere with their killing function. However, among the C3H anti- 
B10.BR sera tested, some were found to have significant inhibitory effects on CML. 
Reproducibility of the inhibitory effect of one of these sera  (N18-I) on B6 and B10 
killers is shown in Table II. In experiments 2  and 3, C3H spleen cells were used as 
targets so that antibodies should not react with target cells. In experiments 1, 4, and 
5,  the  target  cells  used  (K46,  a  BALB/c  tumor)  were  reactive  to  this  non-H-2 
antiserum. However, the antibodies in this serum reactive with the target cells proved 
not to be responsible for the  inhibition observed, as will be shown in the following 
experiments. 
To study whether the observed inhibitory effect of this serum was attributable to 
alloantibodies reactive  with  the  killer  population or  was  of a  nonspecific nature 
independent of their antibody activity, the effects of the serum on killer cells of the 
donor and recipient strains were examined. Because this serum  (C3H anti-B 10.BR) 
should  not  contain  anti-MHC  antibodies,  all  H-2  congenic  strains  on  the  B10 
background  would  be  expected  to  show  reactivity  to  this  serum  similar  to  that 
observed for B10.BR. Therefore, C3H and B 10 cells were sensitized to each other in 
vitro and the inhibitory effect of this serum was assessed on CML of the two reciprocal 
combinations of killers and targets. As shown in Table III, presence of this serum in 
the CML  culture caused significant reduction of specific lysis of target  cells in the 
combination of B10  killers and C3H  targets,  whereas  it  did not  have a  significant 
effect on C3H anti-Bl0 CML. In sharp contrast to this serum, the C3H anti-C3H.SW 
(H--  °k anti-H-2  b)  serum inhibited CML only when target  cells were reactive to this 
serum. This pattern of inhibition is characteristic of anti-H-2 antibodies, as has been 
well documented by many investigators (11,  12). This anti-H-2  b serum had unusually 
high-titered cytotoxic anti-H-2 antibodies (1:5,000  ~1:10,000)  and also  fairly high- 
titered  anti-Ia antibodies.  When  B10  and  C3H  killers,  directed  to  a  third  strain 
(BALB/c, H-2d), were  tested  on  the same target  cell preparation, again, killing by 
B 10 killers was significantly reduced by the C3H anti-B 10.BR serum and C3H killers 
were insensitive. These results indicated that the inhibitory activity of this serum on 
CML  was  not  of a  nonspecific nature and  this  effect  was  achieved  by  antibodies 
reacting with  the  killer population rather  than  with  target  cells.  It  should  be  also 436  BLOCKING CYTOTOXIC  T-CELL  FUNCTION 
TABLE III 
Specificity of CML-inhibiting Antibodies in the C3H Anti-B I O.BR Serum* 
Inhibitor 
Killer-target combination 
B10 anti-  C3H anti-  B10 anti-  C3H anti- 
C3H on C3H  BI0 on B10  BALB/c on  BALB/c on 
K46  K46 
None  17.3 ±  1.1:~  36.2 ±  1.3  47.1 ±  2.0  51.9 ±  1.7 
NMS§  19.1  ±  5.0  35.3 ±  7.2  44.9 ±  1.4  52.4 ±  0.7 
NI8-1 (C3H a-BI0.BR)  8.9 ±  1.0  38.9 ±  7.2  16.2 ±  0.1  40.9 ±  0.2 
B-65 (C3H a-C3H.SW)I  I  14.0 ±  1.3  -4.6 ±  0.5 
* For details see Materials and Methods. 
Percent specific release "4" SD, in the presence of indicated serum. 
§ Normal C3H serum. 
[I H-2~  anti-H-2~ serum. B  10:H-2  ~', C3H:H-2 k. 
noted  that  specificity of killer cells  (i.e., H-2  type of target  cells recognized by the 
killers) did not seem to affect sensitivity to the inhibitory effect of this serum. 
In an attempt to obtain an insight into the genetic basis of the inhibitory antibodies, 
sensitivity of CML  effector cells of various mouse strains to the inhibitory effect of 
this  antiserum  was  examined  (Table  IV).  In  experiment  1,  all  killer  cells  were 
sensitized to H-2  b cells and tested on C3H.SW spleen cells. In experiment 2, all cells 
were sensitized to H-2  a cells and tested on K46 cells. Killer cells of A/J, A.BY, BALB/ 
c,  BALB.B,  B10,  B10.BR,  B10.D2,  and  B6 strains were significantly inhibitable by 
these  sera  whereas  those  of AKR,  CBA/J,  C3H/HeJ,  C3H/HeN,  C3H.SW,  and 
DBA/2 strains were insensitive, and the distinction between the sensitive and insen- 
sitive strains was unambiguous. Complement-dependent cytotoxicity of this serum on 
spleen  cells of representative strains  is  depicted in  Fig.  1.  As anticipated  from  the 
complexity of the genetic differences between the donor and the recipient, this serum 
(C3H  anti-B10.BR)  was  toxic  to  cells of all  strains  except  for  those  on  the  C3H 
background.  In  particular, it should  be noted  that  the serum  was  toxic to  100%  of 
spleen cells from AKR and DBA/2 strains with titers comparable to those on B 10.BR 
and BALB/c cells, respectively. This finding again corroborates the notion that simply 
coating killer ceils with antibodies is insufficient to inhibit their killing function. The 
results of scoring various strains for sensitivity to the CML-inhibiting effect of these 
sera were compared with  the strain distribution of other known  genetic markers.  A 
salient correlation was found between this marker and Lyt-2 phenotypes (Table IV). 
To  study  further  the possible relationship between  the  antigen(s)  responsible for 
the inhibitory effect and Lyt-2-1inked genes as well as Igh-C-linked  genes, killer cells 
from Lyt-2 congenic and  Ig congenic strains were  tested. Among B6  (Lyt-2  b, Igh-C  b, 
B6.Ly2.1  (Lyt-2  ~, Igh-Cb),  C3H.SW  (Lyt2",  Igh-C~),  CWB  (Lyt-2  ~, Igh-Cb),  B10.BR 
(Lyt-2  b, Igh-Cb), and C3H/HeJ  (Lyt-2  ~, Igh-C  ~)  strains, only B6  and  B10.BR  strains 
were significantly sensitive to the inhibitory effect of several different preparations of 
C3H  anti-B10.BR  sera  (Table  V).  Complement-dependent  cytotoxicity  of  serum 
Ld#3  was tested on Ficoll-Hypaque-separated killer populations used in experiment 
4.  As shown  in Fig. 2, this serum killed >98% of in vitro sensitized killer cells of B6, 
B6.Ly2.1, and B 10.BR  strains with almost identical titers. Yet, B6.Ly2.1  killers were 
totally insensitive to the CML-inhibitory effect of this serum  (Table V), symbolizing NOBUKATA  SHINOHARA  AND  DAVID  H.  SACHS  437 
TABLE  IV 
Effect of C3H Anti-B I O.BR Sera on Killer Cells of Various Strains* 
Exp.  1 inhibitor  Exp. 2 inhibitor  Sensi- 
Killer strain:~  tivity§  Lyt-2 
None  NMS  NI8-1  None  NMS  N18-4 
AKR/N  8.511  8.1  9.5  7.0  9.2  9.9  -  1 
A/J  8.9  10.1  0.4  +  2 
A.BY  8.2  9.1  4.3  +  2 
BALB/c  13.0  10.8  2.3  +  2 
BALB.B  11.7  7.4  -0.8  +  2 
B10  18.0  16.2  -1.5  +  2 
B10.D2  8.5  5.6  1.7  +  2 
B10.BR  13.8  13.0  3.7  +  2 
B6  20.8  21.3  8.2  +  2 
CBA/J  8.6  6.8  7.7  17.9  18.2  19.3  --  1 
C3H/HeJ  13.7  12.8  13.1  -  1 
C3H/HeN  8.1  6.0  8.2  21.6  19.0  19.2  -  1 
C3H.SW  18.8  21.7  19.8  -  1 
DBA/2  10.5  13.0  9.6  --  1 
* For details see Materials and Methods. 
Normal splenic lymphocytes of indicated strains were sensitized in vitro to C3H.SW cells (Exp.  1) or to 
BALB/c cells (Exp. 2) and tested on C3H.SW spleen cells (Exp. 1) or K46 tumor cells (Exp. 2). 
§ Sensitivity of killer cells to the inhibitory effect of the C3H anti-B 10.BR serum. 
H  Percent specific release in the presence of the indicated serum. 
BA.B/c 
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FIG.  1.  Complement-dependent cytotoxicity of serum  N18-4  on  spleen cells of various  strains. 
Ordinate indicates percent of spleen cells killed. Abscissa indicates reciprocal of serum dilutions. 
Broken lines indicate complement background. 
the  discrepancy  between  cytotoxic  activity  and  CML-inhibiting  activity  of  these 
antisera.  These  results  suggest  that  the  CML-inhibiting  antibodies  in  these complex 
sera are solely directed  toward  molecules  encoded  by  a  single genetic  locus linked  to 
or identical  with  Lyt-2. 
The  experiments  shown  thus  far, established  the  genetic  linkage  or identity  of the 
gene(s)  encoding  the  molecules  reactive  with  the  CML-blocking  antibodies  and  the 
Lyt-2 locus.  However,  because  of the complexity  of the C3H  anti-B 10.BR  sera,  it was 438  BLOCKING CYTOTOXIC T-CELL FUNCTION 
TABLE  V 
Inhibitory  Effect of C3H Anti-B I O.BR Sera on Kilter Cells of Congenic Strains* 
Specificity 
of killers'[" 
Target  Inhibitor§ 
Killer strain 
B6  B6.Ly2.1  C3H.SW  CWB  BI0.BR  C3H 
Exp.  1 
a  H-2  a  K46 
Exp  2 
fill-2  a  C3H 
spleen 
Exp 3 
a-H-2  k  C3H 
spleen 
Exp. 4 
a-H-2  a  K46 
None  23.5 ±  3.21l  23.0 ±  1.4  183 ±  4.2  13.9  +  1.7 
nl C3H  22.8 ±  2.0  25.1  ±  0.3  21.7 ±  5.1  19.4  ±  6.5 
NI8-1  12.3  ±  3.8  24.3 ±  2.8  19.8  ±  1.9  17.8  ±  0.3 
None  25.8 ±  5.0  17,4  ±  0.5 
nl C3H  20.5 ±  2.0  18.3  ±  5,5 
N18-4  11.9  ±  5.3  21.4 +  0.7 
None  14.2  ±  1.8  12.3  ±  2.0 
nl C3H¶  6.5 ±  1.8  5.3 ±  0.9 
N18-4  4.1  ±  1.7  12.1  ±  0.3 
None  26.3 ±  1.3  20.6 ±  0.5  45.9 ±  1.7  24.4 +  0.5  20.6 +  1.0  22.7 ±  1.3 
nl C3H  25.5 ±  0.8  18.1  +  0.7  41.9 ±  1.1  23.6 ±  2.3  20.1  ±  2.8  19.7  ±  1.4 
N23-5  117 ±  0.7  22.1  ±  0.1  43.3 ±  5.1  30.7  ±  0.4  8.5  ±  0.7  24.1  ±  0.9 
Ld#3  14.8  ±  1,2  21.8 ±  1.9  42.7 ±  2.2  25.0 ±  0.3  103  ±  11  20,5  ±  1.7 
* For details see Materials and Methods. 
]" ~-H-2a: cells were sensitized to BI0.D2 cells, a-H-2k: cells were sensitized to C3H cells. 
§ N18-1, NI8-4 and lz~3: C3H/HeJ anti-BI0.BR. N23-5: C3H/HeN anti-B 10.BR.  After the initial discovery of the inhibitory ~erum  (NI8- 
1), sera from  individual mice were screened for CML-inhibiting activity, and only strongly positive sera were pooled (N18-4, N23-5). The 
immune sera from  mouse Ld#3 showed extraordinarily high specific  inhibitory activity, therefore the sera from  this single mouse were pooled 
separately. Serum Iz~3 was used at  1:8 dilution in this experiment. 
II  Percent specific  release in the presence of the indicated serum  ±  SD. 
¶ This batch of normal C3H serum showed  nonspecific  inhibitory effect  on CML. It also inhibited C3H killer cell  function.  However, the 
specific  inhibition by serum N18-4 was clearly distinguishable as the data show. 
v' 
>90 /  •  : 
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16  64  25619244996 
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I  C3H=.,  ,  ~  ~  ~  =  i 
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Flo.  2.  Cytotoxicity of serum Ld#3  (C3H anti-Bl0.BR)  on in vitro sensitized killer cell popula- 
tions.  Day 5  in vitro sensitized killer cells used  in  Exp.  4  of Table V  were tested  for reactivity to 
serum Lo~3 by a complement-dependent cytotoxicity assay, Ordinate: percent dead cells: abscissa: 
serum dilution  -] . 
not possible to study the correlation between anti-Lyt-2 antibody activity and CML- 
blocking activity of these sera. Therefore, an attempt was made to raise CML-blocking 
sera in  an  Ly2 congenic  combination  (i.e.,  conventional  anti-Ly2.2  antisera).  Four 
(C3H  X  B6.Ly2.1)F1  mice were  immunized with  a  mixture of thymocytes, spleen 
cells,  and  lymph  node  cells  from  normal  B6  mice.  After  10  immunizations,  two 
animals started to produce detectable amounts of CML-inhibiting antibodies, whereas NOBUKATA SHINOHARA AND  DAVID  H.  SACHS  439 
TABLE VI 
Comparison of Anti-Lyt-2 Cytotoxic Antibody Activity and CML-blocking 
Activity of Anti-Lyt-2 Sera* 
(C3H  ×  B6-  Blocking ofCML 
Ly2.1)FI  Anti-Lyt-2~ 
anti-B6 ani-  activity  B 10 anti-BALB  C3H.SW anti- 
real number  on K46  BALB on K46 
No. 
--  --  36.0 4- 0.2§  10.6 4- 0.5 
596  1:40  34.7 4- 0.8  11.9 :lz 0.5 
597  1:1280  30.0 4- 0.6  12.2:1:0.6 
598  1:320  20.1:1:0.6  11.4 :tz 0.4 
599  1:320  8.8 4- 0.5  8.6:1:1.0 
* Four (C3H ×  B6.Ly2. I)Fj mice were immunized with a mixture of thymus, 
spleen, and lymph node cells from normal B6 mice. Results shown here are 
for sera collected 7 d after the 12th immunization  of each animal. 
:~ Complement-mediated cytotoxicity on B6 thymocytes. All four sera killed 
80-90% of B6 thymocytes.  None showed detectable cytotoxic activity on 
B6.Ly2.1 thymocytes. 
§ Percent specific release in the presence of the indicated serum. 
the other two did not. Individual sera obtained after 12 immunizations were examined 
for their CML-blocking activities and  their anti-Lyt-2 antibody activity was  deter- 
mined by complement-mediated cytotoxicity on B6 thymocytes (Table VI). Sera from 
animals 596  and  597  did not  show appreciable CML-blocking activities. The other 
two sera (particularly 599)  caused significant specific reduction of target cell killing 
by  B6  killer cells when  added  to  CML  culture.  All four sera killed 80-90%  of B6 
thymocytes in the presence of rabbit complement with different titers. However, there 
was no apparent correlation between cytotoxicity on thymocytes and CML-blocking 
activity of the  sera.  For example, serum  597  showed  poor CML-blocking activity, 
whereas it showed relatively high cytotoxic activity on B6 thymocytes. Serum 599, on 
the other hand,  produced potent CML-blocking, although its cytotoxic activity was 
not as high as that of serum 597. This discrepancy could be a  result of differences in 
the immunoglobulin class of the dominating antibodies in individual sera, or could 
indicate that CML-blocking activity is not a  result of antibodies specific for conven- 
tional Lyt-2 molecules, but rather a  result of antibodies directed to as yet undefined 
molecules encoded by Lyt-2-1inked genes. 
Discussion 
Allogeneic killer cells are generally resistant to treatment with allo- and xenoantisera 
in the absence of complement  (6). Among the few positive reports of such treatments 
is that of Kimura (7), who reported that a rabbit xenoantiserum raised against in vivo 
sensitized mouse  alloreactive cells inhibited the allogeneic CML  of the same strain 
combination as used for immunization. The inhibitory activity of this antiserum was 
attributed to possible anti-idiotypic antibodies reactive with  the antigen combining 
site of the  relevant T-cell receptors  (7),  but  the  nature  or  genetics of the  putative 
receptor were  not  elucidated.  Recently,  Redelman  and  Trefts  obtained  goat  anti- 
rabbit  xenoantibodies  capable  of  inhibiting  rabbit  anti-mouse  CML  (8).  In  this 
laboratory,  several  xenogeneic  anti-mouse  lymphocyte sera  were  found  to  contain 440  BLOCKING CYTOTOXIC T-CELL FUNCTION 
antibodies  which  inhibited  mouse  allogeneic  CML  in  the  absence of complement, 
and at least one component of such inhibitory activity was attributable to antibodies 
reacting with killer cells (N. Shinohara, unpublished observations). However, the use 
of  xenogeneic  antisera  introduced  numerous  complexities  making  an  analysis  of 
molecules and  mechanisms responsible for the observed inhibitory effect extremely 
difficult. 
There have previously been no successful reports on attempts to block the effector 
function of allogeneic killer cells with alloantibodies in the absence of complement. 
Similarly,  most  of our attempts to raise such  alloantibodies  failed  (Table I).  Even 
antisera reactive with T  cells with extraordinarily high titers did not affect allogeneic 
killing.  Thus, because the coating of killer cells with antibodies to most cell surface 
alloantigens does not affect their function, our observations strongly suggest a  func- 
tional significance of the molecules reactive with CML-blocking alloantibodies. 
Among  our  attempts  at  alloimmunization,  successful  results  have  so  far  been 
obtained only in the combination C3H anti-B10.BR.  Even in this combination, not 
all immune animals produced CML-inhibiting antibodies. Although two-thirds of the 
immunized animals started to produce detectable amounts of inhibitory antibodies 
after >10  immunizations,  very few mice  (10-15%)  produced  a  sufficient amount  of 
inhibitory  antibodies  to  allow  analytical  experiments.  The  earliest  production  of 
inhibitory  antibodies  was  observed  after  four  to  six  immunizations  in  exceptional 
animals which  became good  producers  later.  Considering  this experience,  it  seems 
likely that  CML-inhibiting  activities may have been  lost  by pooling immune sera 
before screening in some cases. Thus,  it is possible that  in combinations other than 
C3H anti-B 10.BR, CML-inhibiting antibodies could be raised if individual  animals 
were screened. 
The inhibitory effect we have studied is attributable to the reactivity of antibodies 
with a  killer cell population rather than with target cells, because killer cells of the 
donor strain background are sensitive to the inhibitory activity, but those of recipient 
background are not. Killer cells of the sensitive strains are inhibited  by the antisera 
irrespective of H-2  types of the  targets  they  recognize.  In  addition,  these  non-H-2 
antisera do not interfere with target cell lysis even when they react with target cells 
(Tables III-V). 
The strain  distribution  of sensitivity of killer cells  to  the  inhibitory effect of the 
C3H  anti-B10.BR  antisera  is  very  well  correlated  with  that  of the  Lyt-2 b  allele. 
Furthermore, the B6.Ly2.1 strain, which differs from the B6 strain at a chromosomal 
segment  including  the  Lyt-2  locus,  is  insensitive  to  the  inhibitory  effect  of these 
complex sera. The genetic specificity of this antibody activity is reinforced by the fact 
that CML-blocking antibodies could be raised in an Lyt-2 congenic pair (Table VI). 
No  apparent  correlation  was  seen  between  complement-dependent  cytotoxicity  of 
antisera on spleen cells or on in vitro sensitized killer cell populations and inhibitory 
activity of the sera on  killer  cells of the  same strain.  These data  indicate  that  the 
CML-inhibiting  activity of these antisera  is  dependent  only on  their  reaction  with 
products of genes linked to or identical with the Lyt-2 locus. 
The identity of the molecules responsible for the antibody-mediated inhibition  of 
CML still remains to be studied.  Earlier reports by other investigators have suggested 
that anti-Lyt-2 antibodies do not inhibit CML (6,  13). The discrepancy between the 
present observation and those observations might imply that the molecules reactive NOBUKATA SHINOHARA AND DAVID H.  SACHS  441 
with the inhibitory antibodies are not  Lyt-2 molecules but rather distinct  molecules 
encoded by Lyt-2-1inked genes. The discrepancy between anti-Lyt-2 cytotoxic antibody 
activity and CML-blocking activity in  the sera raised in  the Lyt-2 congenic combi- 
nation we have studied also casts doubt on the identity of the molecules reactive with 
CML-blocking antibodies. However, this discrepancy may be explained by differences 
in  the  immunoglobulin  class  of the  dominating  antibodies  in  individual  sera,  a 
possibility we are presently investigating. It is important to note that if antibodies to 
products of a  gene closely linked to Lyt-2 were responsible for the blocking observed, 
it is quite likely that such antibodies would be included as contaminants in conven- 
tional anti-Lyt-2 (and perhaps anti-Lyt-3) sera. Studies using monoclonal anti-Lyt-2 
hybridoma antibody are also in progress to try to answer this question (N. Shinohara, 
U. Hammerling, and D. H. Sachs, manuscript in preparation). 
At present, we can only speculate on the possible mechanisms of the inhibition of 
CML we have observed. The most trivial possibility might be agglutination of killer 
cells  by  antibodies.  Massive  agglutination  could  perhaps  prevent  killer  cells  from 
contacting target cells. Although  this possibility has not been formally ruled out,  it 
does not seem likely, because exposing killer ceils to high-titered antibodies of other 
specificities did not inhibit their killing function  (Tables I, III-V, Figs.  1 and 2). 
A  second possibility is alteration of the cell surface by antibodies which somehow 
results in the inability of killer cells to achieve normal function.  Because many other 
antibodies reactive with T  cells failed to cause inhibition, this model requires a certain 
peculiar  nature  of the  molecules  reactive  with  the  inhibitory  antibodies.  Such  a 
relationship  could be a  close physical association of the Lyt-2-related determinants 
with some functional molecule necessary for killing. Even without physical association 
of the  two  kinds  of molecules,  such  specific  interference  might  occur,  as  has  been 
exemplified in blocking of B-cell Fc receptors by anti-Ia antibodies (14). 
A third possibility is that the inhibitory antibodies react with functional molecules 
other than antigen receptors. After interacting with the antigen on target cells, killer 
cells  may  deliver  a  killing  message  to  the  target  cells  through  mediators  either 
expressed on  their  surfaces  or released  locally.  If the  antibodies  reacted  with  such 
molecules, killing might not  take place. The Lyt-2 antigen  has been shown  to be a 
marker  for a  subpopulation  of T  cells  with  certain  functions  including  killer  and 
suppressor cells (15-17).  If Lyt-2 molecules were the mediators of killing, this might 
explain the correlation between this surface marker and the function of cells bearing 
the molecules. However, this explanation would not  account  for the fact that  many 
immature peripheral T  cells and thymocytes also bear Lyt-1, 2, and 3  (18,  19). 
Perhaps  the  most  attractive  possibility  is  that  the  observed  inhibition  reflects 
interaction  of anti-receptor antibodies and antigen-recognition structures of killer T 
cells.  In  this  model,  the  anti-receptor  antibodies  would  be  directed  to  a  constant 
portion of the receptor, because they inhibit  the function of killer cells with various 
different specificities, i.e., anti-H-2  d, anti-H-2  k and anti-H-2  b. Of course, this apparent 
lack of killer specificity could be explained by the presence of multiple anti-idiotypic 
antibodies  in  the  serum  and  absorption  studies  would  be  required  to  distinguish 
between  these  possibilities.  If Lyt-2 molecules were the  antigen-receptor molecules, 
this  would  provide  a  possible  explanation  for  the  presence  of Lyt-2  molecules  on 
immature T  cells and thymocytes. Recent investigations on the ontogeny of the T-cell 
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so that the repertoire of mature T  cells is restricted in terms of selfreactivity (20).  If 
this  is  true,  precursor T  ceils should  express their clonal  marker,  i.e.,  receptors, on 
their surface so as to be subjected to such selection before full differentiation. 
One of the difficulties with this model is the fact that certain populations of T  cells 
lack the Lyt-2 marker (14-16). These include helper cells and/-region-specific mixed 
leukocyte  reaction  (MLR)-reactive  cells.  One  would  thus  have  to  postulate  the 
existence of two separate sets of genes coding for T-cell receptors, one for Lyt-23- cells 
and  another  for  Lyt-23  +  cells.  Idiotypes of T-cell  receptors  have  been  intensively 
studied  recently  (reviewed in references 2  and  3),  and  these studies  have suggested 
that at least a  part of the antigen-combining portions of T-cell receptors is encoded 
by  genes  linked  to  the  immunoglobulin  heavy  chain  allotype  locus.  The  T  cells 
involved  in  these  studies  were  helper  cells  and  MLR-reactive cells,  both  of which 
functions are predominantly attributed to Lyt-23- cells in the mouse (15,  16). So far, 
no genetic relationships of receptors of Lyt-1-23  + cells to Ig heavy chain genes have 
been demonstrated.  It is tempting to speculate that different subsets of T  cells could 
use different sets of genes for their receptors, Ig heavy chain-linked genes for the Lyt- 
1+23- population and Lyt-2-1inked genes, perhaps r-light chain-linked genes (21, 22), 
for Lyt-23  + cells. In this regard, we intend  to examine the effects of our alloantisera 
on other functional T-cell subsets. If similar blocking activities are found, it will be of 
interest to determine the genetic relationships of the relevant targets. 
Summary 
In an attempt to produce alloantibodies to cytotoxic T-cell receptors, hyperimmune 
anti-lymphocyte antisera  have been  raised  in  mice of various  strain  combinations, 
and have been tested for their ability to block allogeneic cell-mediated lymphocyto- 
toxicity (CML)  in the absence of complement at the T  killer cell level. Most of the 
sera  failed  to  show  any  significant  and  reproducible  inhibitory  effects.  However, 
among C3H anti-B 10.BR antisera, some sera were found to be capable of significantly 
inhibiting  CML.  This effect was attributable  to  antibodies  reacting with  the  killer 
population rather than the target cells, because the sera inhibited B 10 anti-C3H CML 
but not C3H anti-B10 CML.  Among mouse strains tested, A/J,  BALB/c, B10, and 
B6 strains were sensitive to the inhibitory effect of the sera whereas AKR, CBA, C3H, 
and  DBA/2  strains were insensitive.  This sensitivity of killer cells to the  inhibitory 
effect  correlated  well  with  the  strain  distribution  of the  Lyt-2.2  antigen.  In  the 
presence of complement, these same sera were toxic to  100% of spleen cells of AKR, 
BALB/c,  BI0,  and  DBA/2  strains,  with  comparable  cytotoxic  titers.  Thus,  the 
inhibitory activity of the sera could not be explained by nonspecific effects of high- 
titered  antibodies.  To study the  relationship  between  the antigen(s)  responsible for 
the blocking effect and Lyt-2-1inked genes, killer cells from Lyt-2 congenic strains were 
tested and conventional anti-Lyt-2.2 antisera were raised in an appropriate congenic 
strain  combination.  Killer  cells  from  B6,  but  not  from  B6.Ly2.1  animals,  were 
significantly sensitive to the blocking effects of the inhibitory C3H anti-B 10.BR sera. 
The conventional anti-Lyt.2.2 sera did produce CML blocking,  although  there was 
no apparent  correlation between  such  blocking and  the anti-Lyt-2.2 cytotoxic titer. 
These  results  thus  indicate  that  the  target  molecules  responsible  for  blocking  of 
killer cells are encoded  or regulated  by genes that  are closely linked  to or identical 
with Lyt-2. NOBUKATA SHINOHARA AND DAVID H.  SACHS  443 
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